Sample size estimation and power calculations for vaccine efficacy trials for exceedingly rare diseases by Loiacono, Matthew M
SAMPLE SIZE ESTIMATION AND POWER CALCULATIONS FOR VACCINE 
EFFICACY TRIALS FOR EXCEEDINGLY RARE DISEASES 
by 
Matthew M. Loiacono 
BA, Biology, Franklin & Marshall College, 2015 
Submitted to the Graduate Faculty of 
Department of Biostatistics 
Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Master of Science 
University of Pittsburgh 
2018 
ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
This thesis was presented 
by 
Matthew M. Loiacono 
It was defended on  
April 11th, 2018 
and approved by 
Thesis Advisor:  
Hanna Bandos, PhD 
Research Assistant Professor, Biostatistics 
Graduate School of Public Health 
University of Pittsburgh 
Committee Members: 
Robert Krafty, PhD 
Associate Professor, Department of Biostatistics 
Graduate School of Public Health 
University of Pittsburgh 
Willem G. van Panhuis, MD PhD 
Assistant Professor, Epidemiology 
Assistant Professor, Biomedical Informatics 
Affiliated Faculty, Public Health Dynamics Lab 
School of Medicine and Graduate School of Public Health 
University of Pittsburgh 
iii 
Copyright © by Matthew M. Loiacono 
2018 
iv 
ABSTRACT 
The implementation of vaccines is one of the most profound advancements in the world of 
public health. While the scientific process underlying vaccine development is important, 
determining a vaccine’s efficacy and safety profile would not be possible without vaccine efficacy 
trials. In terms of trial design, sample size estimation is one of the essential considerations to be 
made, ensuring that the trial achieves the targeted power, minimizing chances of a false-negative 
finding.  
An often considered hypothesis for such trials is testing if a new vaccine is more efficacious 
than a placebo or the current standard-of-care. We investigated two relevant methods, the Z-Test 
Normal Approximation and the Exact Conditional Test under Poisson Assumption as presented by 
Chan and Bohidar. While the Normal Approximation is a generally acceptable method, the Exact 
Conditional approach may be better suited for trials with low disease incidence. 
In this Thesis, we develop SAS code for estimating sample size via both methods, in 
addition to calculating exact power. Sample size and power calculations are performed under a 
range of different scenarios, stratified by high, intermediate, and low incidence of disease in the 
control group. Furthermore, under each scenario, simulations are utilized to evaluate the 
performance of the Exact Conditional approach. 
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Both methods are generally reasonable approaches to sample size estimation and power 
calculations for vaccine efficacy trials. In trials of higher disease incidence, the Normal 
Approximation is simpler to implement, and should adequately power the trial. For scenarios of 
low incidence (< 0.01), the Exact Conditional approach may be more favorable, as it may provide 
greater power to the trial. To minimize the chance of an underpowered trial, we propose 
implementing a strategic inflation of sample size. Lastly, we highlight the importance of 
congruency between methods used for sample size estimation, trial design, and data analysis. 
Public Health Significance: Vaccine efficacy trials are required for vaccine licensure and 
distribution to the public. A robustly estimated sample size is crucial, as it ensures a trial is 
adequately powered, thereby improving the odds of obtaining conclusive results. The methods 
investigated here represent viable approaches to sample size estimation for such trials.  
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1.0 INTRODUCTION 
1.1 HISTORICAL OVERVIEW 
Throughout the history of public health, there have been a number of particularly notable 
achievements that have not only altered the course of public health history for the better, but more 
importantly, have drastically improved health at an individual and population level. Some of these 
advancements and discoveries made in the 20th century include, but are not limited to, the 
fluoridation of drinking water, control of infectious diseases, standardization of motor-vehicle 
safety, and implementation of workplace safety protocols. These advancements, alongside many 
others, have made for an overall healthier population, with greater quality and quantity of life, all 
while dramatically reducing associated health care costs (Porter, 1999). However, aiding in the 
near-eradication of countless harmful diseases, the wide-scale implementation of vaccines is 
certainly one of the most profound advancements in the world of public health. 
Although vaccines are frequently considered to be an advancement associated with the 
aforementioned 20th century public health advancements, the first known use of a vaccine, as we 
know them, dates back to the late 18th century. Edward Jenner, a country doctor in rural England, 
performed what we now regard as one of the first legitimate clinical trials. Jenner discovered that, 
by inoculating an individual with pus from a cowpox lesion, immunity to any subsequent 
exposures of small pox could be developed (Jenner, 1798; Stern & Markel, 2005). However, he 
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was not the first individual to attempt creating immunity via inoculation. The process of 
inoculation can be traced to the 15th century across parts of Asia, where subjects were 
inoculated with the live small pox virus. This particular method, though, was not only more 
dangerous, due to use of the live virus, but also less effective at producing immunity to repeated 
exposures (Plotkin, 2011). Jenner’s method of inoculation, using a less dangerous variant of the 
virus, marked a turning point in the history of immunization, allowing us to create immunity well 
beyond the first or second exposure to a virus. His discovery, ultimately, laid the groundwork for 
the future of immunizations and vaccines. 
Over the course of the following century, the small pox vaccine, as defined by Jenner, 
would go on to be used throughout Europe and the United States (Strassburg, 1982). Worthy of 
noting, the word vaccine, as Jenner had used it, was derived from the term Variolae vaccinae, or 
cowpox (Jenner, 1798). According to the World Health Organization, as of 2018, “a vaccine is a 
biological preparation that improves immunity to a particular disease… made from weakened or 
killed forms of the microbe, its toxins, or one of its surface proteins” (WHO, 2018). With that said, 
Jenner’s smallpox vaccine would not meet the modern-day definition of a vaccine.  
Nearly 100 years after the work of Jenner, it was the work of French chemist Louis Pasteur 
and his colleague, Emile Roux, that helped broaden and shape the definition of vaccines. Pasteur 
and Roux developed the first rabies vaccine by attenuating rabies grown in live rabbits in a lab 
setting. First tested on canines, and then on a small number of people over the course of the 19th 
century, their vaccine revealed its incredibly high success rate with minimal side effects (Geison, 
2014). While this vaccine would now be more accurately described as an antitoxin, it nevertheless 
helped expand the definition of vaccines to include treatments beyond Jenner’s cowpox vaccine. 
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Although many others contributed to the historical development of vaccines, Jenner, Pasteur, and 
Roux are worthy of highlighting, due to their particularly influential contributions. 
1.2 MODERN DAY AND CLINICAL TRIALS 
As of 2018, there are nearly 100 vaccines approved for use in the United States, with an estimated 
21 million hospitalizations and 700,000+ deaths having been prevented between 1994-2014, due 
to vaccines (CDC, 2014; FDA, 2018). Similarly, an estimated 2-3 million deaths are prevented 
annually across the globe as a result of vaccine implementation. The realized benefits of 
vaccination as a form of preventive care, in terms of overall population health as well as associated 
health care costs, are not to be underestimated (WHO, 2017). Although the scientific discovery 
process that underlies vaccine discovery and development is certainly fundamental to bringing 
these vaccines to the public, the rigorous testing protocol to determine their effectiveness as well 
as any potential side effects is paramount to their licensure, distribution, and successful 
implementation. 
In order for any new pharmaceutical product to be released to the general public, each 
product must be assessed over a series of tests, or clinical trial phases. Prior to the initiation of a 
clinical trial for a new product, however, certain preclinical studies must first be performed. 
Primarily relying on animal testing, preclinical studies are intended to determine a safe baseline 
dosage for the first phases of the clinical trials, while also providing a preliminary assessment of 
the product’s safety. Species are chosen to ensure maximum relatability to humans and in doing 
so, safe baseline dosages can be estimated allometrically (Atanasov et al., 2015). Following 
preclinical studies, phases 0-IV of the clinical trial introduce human subjects and allow for further 
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assessment of product safety, dosing, and efficacy. Phase 0, introduced by the FDA in 2006, is an 
exploratory investigational study in which a small number of subjects (usually less than 20) receive 
a micro-dose of the product to demonstrate possible therapeutic benefits. This phase serves as a 
way of quickly separating effective from ineffective new products, and is not required for product 
licensure (Fromer, 2006). More traditionally, clinical trials begin with phase I, a study intended to 
establish the dose and schedule of a drug, conducted on a small cohort of volunteers. Design for 
phase I trials varies based on the drug and the results from the preclinical studies, but one of the 
most common methods is the “3 + 3” dose-escalation design. Differences in particular designs 
aside, phase I trial designs expose all subjects to the drug and aim to implement escalating doses 
and varied scheduling to ultimately determine the recommended phase II dose, in addition to the 
drug’s safety (Hansen, Graham, Pond, & Siu, 2014; Le Tourneau, Lee, & Siu, 2009).  
While phase 0 and I trials establish the baseline dosing, safety, and scheduling, a phase II 
trial, conducted in up to several hundred individuals, serves to further investigate the new drug’s 
efficacy, dosing, and safety profile, in addition to potentially adverse effects. In general, the most 
commonly used design in phase II trials is a single-arm trial. However, in some cases, a 
randomized control design may also be implemented, where the control group receives the current 
standard-of-care, if it exists (Mandrekar & Sargent, 2010).  
After a successful phase II trial, a large scale phase III trial is conducted to more precisely 
assess these same characteristics across a larger group of patients. Phase III trials follow a 
randomized control design, and generally include anywhere from 250-3,000 individuals, with 
varying levels of risk. It is possible that the size of these trials can even reach upwards of 10,000 
individuals. In terms of treatment, in some special cases, individuals may continue to receive 
treatment outside of the trial to maintain the therapeutic benefits while the drug is undergoing 
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licensing. This particular type of trial is referred to as phase IIIB trial (Friedman, Furberg, DeMets, 
Reboussin, & Granger, 2015).  More generally, a phase III trial helps investigators to get a much 
more accurate estimate of the drug’s true efficacy. Following a successful phase III trial, a drug 
receives its licensure and is then ready to be released to its target market or the general public.  
Once a drug has received licensing and complete the phase III trial, a phase IV trial can 
take place. As opposed to the experimental nature of phase 0-III trials, a phase IV trial is an 
observational trial in nature. Although not all phase IV trials are the same, the majority take shape 
as post-marketing surveillance. Phases 0-III trials help to identify most adverse effects, but in the 
case of excessively rare adverse effects, the phase IV trial is crucial to identifying these events 
(Mitchell, Philipose, & Sanford, 1993; Suvarna, 2010). Semantics aside, this generalized outline 
of clinical trials is applicable to nearly all new pharmaceutical products, including the vast 
majority of vaccines. 
1.3 VACCINE EFFICACY TRIALS AND SAMPLE SIZE ESTIMATION 
While assessing the safety profile and dosing schedule of a new vaccine are both important aspects 
of its development, the primary objective in conducting clinical trials is to establish the efficacy of 
the vaccine in question. In establishing the efficacy, more specifically, investigators aim to 
demonstrate that the test vaccine reduces the incidence of a particular disease, relative to a placebo 
or the standard-of-care. In terms of the physiological components, preclinical studies and phase I 
trials are useful to establish these characteristics, therefore setting the stage for phases II-IV. 
However, from a statistical standpoint, one of the vital calculations to be made for a vaccine 
6 
efficacy trial is the sample size estimation, that helps ensure the pre-specified statistical power is 
achieved, thus minimizing the chance of a false negative finding.  
Prior to sample size estimation, the desired minimum power for the trial must first be 
specified, usually by the lead investigator(s) and/or statisticians involved in the trial design. 
Similarly, the significance level of the test must also be specified during the earlier trial design 
stages, where the level of the test is indicative of the maximum allowed chance of a Type I error 
rate, or false-positive rate. After establishing the desired level of the test, power for the trial, and 
anticipated effect size, the expected required sample size can be estimated. This calculation is 
crucial for a number of reasons, and over or underestimation can have a range of negative 
consequences. An incorrectly calculated sample size, where the sample size is underestimated, can 
result in the specified power never being achieved, potentially leading to inconclusive results. As 
phase II-IV clinical trials become larger and more costly, an overestimated sample size, 
conversely, could incur unnecessarily high expenses for the organization leading the clinical trial 
(Sakpal, 2010).  
Different approaches exist to calculating a sample size for a vaccine efficacy 
trial, depending on the hypothesis being tested. In regards to the classical test of 
comparing two proportions or incidences, appropriate sample size formulas have been derived 
(Breslow & Day, 1987). However, these methods cannot account for a non-zero bound for the 
value of the null vaccine efficacy, and are thus limiting in terms of the scope of their 
applicability. Different test statistics have been proposed for this precise situation, and 
corresponding asymptotic sample size calculations have also been derived (Chan & Bohidar, 
1998; Chow, Shao, & Wang, 2003; Farrington & Manning, 1990; Gart & Nam, 1988; 
Miettinen & Nurminen, 1985). Although these methods take into account a non-zero lower 
bound, they may not be optimal for trials with a large 
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sample size and excessively low disease incidence. For this type of scenario, an exact conditional 
test where the number of cases is assumed to follow a Poisson distribution has been previously 
presented by Breslow and Day, and further modified by Chan and Bohidar to account for 
hypotheses with a non-zero lower bound (Bohidar & Chan, 1996; Breslow & Day, 1987; Chan & 
Bohidar, 1998).  
In this paper, we investigated the sample size estimation methods as presented by 
Chan and Bohidar, including the Z-Test Normal Approximation and the Exact Conditional Test 
under Poisson Assumption (Chan & Bohidar, 1998). In Section 2.1, the concepts of statistical 
power and level of the test are reviewed. In Section 2.2, the specific hypothesis of interest for a 
vaccine efficacy trial is established. Two approaches to power and sample size calculation are 
presented in Sections 2.3 and 2.4. In Section 2.5, a description is provided of the software used to 
program both of these methods, as well as our algorithm to determine the correct required number 
of cases for the Exact Conditional approach. In Section 2.6, the chosen scenarios for projecting 
sample size are discussed. Our results are presented in Section 3.  Lastly, in Section 4, our findings 
are summarized, the importance of continuity in trial design and analysis is highlighted, and a 
potential strategy to help avoid under-powering a trial is proposed. 
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2.0 METHODS 
2.1 POWER AND ALPHA LEVEL OF THE TEST 
Two vital parameters that must be specified, prior to sample size estimation, are the significance 
level of the test and the minimum desired statistical power for the trial. In specifying the level of 
the test, the investigator is establishing the maximum chance of a Type I Error, or false-positive, 
which is denoted as (α). Generally, the level of the test is designated within the range of 2.5% to 
5%. The power of the study is the likelihood to detect a protective effect of the vaccine, if the 
vaccine does in fact have a protective effect. We denote power as (1-β), where (β) is the 
probability of making a Type II Error, or a false-negative. Clinical trials are generally designed to 
achieve a minimum of 80% power (Chow et al., 2003). Studies can be designed to have a targeted 
power greater than 80%, but this will usually result in a substantial increase in the sample size. 
2.2 HYPOTHESIS TESTING 
For the simplicity of the presentation, all of the formulas here are presented for a case of equal 
sample sizes between the test and control groups. Let us define n as the number of patients in each 
group, P1 as the incidence of disease in the control group, and P2 as the incidence of disease in the 
test vaccine group, where P2 < P1. We then denote vaccine efficacy (π) as (1 – relative risk) of test 
subjects having the disease relative to control subjects: 
(1)  𝜋 =  1 – (𝑃2 / 𝑃1) 
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In the case of a vaccine efficacy trial, where a pre-existing vaccine is already the standard-
of-care, we generally refer to the new vaccine’s expected efficacy as the relative vaccine efficacy, 
a term that is frequently used in vaccine efficacy studies of this nature (Ashkenazi et al., 2006; 
Comstock, 1994; DiazGranados et al., 2014; Storsaeter & Olin, 1992). Therefore, the relative 
vaccine efficacy value is not the test vaccine’s true efficacy, but rather, it is the test vaccine’s 
efficacy in relation to the control vaccine’s efficacy (Shim & Galvani, 2012). In either case, 
whether we are working with a relative vaccine efficacy of the new test vaccine and standard-of-
care, or simple vaccine efficacy compared to a placebo, the general process of hypothesis testing, 
power calculation, and sample size estimation remain the same. 
In a vaccine efficacy trial, we are interested in determining whether or not a new vaccine 
is more efficacious than the control. Specifying a minimum vaccine efficacy level of the new 
vaccine, denoted as π0, the hypothesis used to test that the new vaccine is more efficacious than 
the control is represented as follows: 
(2) 𝐻0:  𝜋 ≤ 𝜋0   𝑣𝑒𝑟𝑠𝑢𝑠    𝐻1:  𝜋 > 𝜋0
For a trial with measurements of relative vaccine efficacy, π0 would be set equal to zero, 
as the new vaccine’s efficacy is relative to that of the control. If the control group is entirely 
unvaccinated, then π0 would be set to a value greater than zero, to test whether or not the new 
vaccine’s efficacy is greater than π0, thus demonstrating some level of efficacy. 
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2.3 Z-TEST NORMAL APPROXIMATION
For the Z-Test Normal Approximation method, we used the test statistic that has been previously 
established, for the given hypothesis (2) (Chan & Bohidar, 1998; Farrington & Manning, 1990; 
Miettinen & Nurminen, 1985):  
(3)  𝑍 =
?̂?2 − (1−𝜋0)?̂?1
?̂?0 √𝑛⁄
(4) ?̂?0 = [𝑃2̃(1 − 𝑃2̃) + (1 − 𝜋0)
2 𝑃1̃(1 − 𝑃1̃)]
1 2⁄
Here, small values of the Z statistics provide evidence against the null hypothesis. In this case, ?̂?1 
and ?̂?2 are the observed incidence in the control and test groups, respectively, and 𝑃1̃ and 𝑃2̃ are
the maximum likelihood estimates of P1 and P2, within the confines of the null hypothesis (Chan 
& Bohidar, 1998). In this test statistic, n represents the sample size of either the control or test 
group, in accordance with our assumption of equal sample sizes between the test and control 
groups. 
Based on this test statistic, asymptotic formulas for power and sample size have also been 
previously derived (Chan & Bohidar, 1998). Firstly, the limiting values of  𝑃1̃ and 𝑃2̃  can be
denoted as 𝑃1̅ and 𝑃2̅̅ ̅ . Using the planned incidence in the test and control vaccine groups, P1 and
P2, the respective values of 𝑃1̅ and 𝑃2̅̅ ̅ can be determined as follows:
(5) 𝑃2̅̅ ̅ = {𝑎 − [𝑎
2 − 8𝑏]1 2⁄ }/4      and       𝑃1̅ = 𝑃2̅̅ ̅/(1 − 𝜋0)
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where, the values for a and b in this expression can be calculated as such: 
(6) 𝑎 = (1 − 𝜋0)(1 + 𝑃1) + 1 + 𝑃2  and      𝑏 = (1 − 𝜋0)(𝑃1 + 𝑃2)
Consequently, 𝑃1̅ and 𝑃2̅̅ ̅ can then be used in place of 𝑃1̃ and 𝑃2̃ in (4) to determine the limiting
value of ?̂?0, denoted as 𝜎0̅̅ ̅: 
(7) 𝜎0̅̅ ̅ = [𝑃2̅̅ ̅(1 − 𝑃2̅̅ ̅) + (1 − 𝜋0)
2 𝑃1̅(1 − 𝑃1̅)]
1 2⁄
Furthermore,  𝜎1 can be calculated by replacing 𝑃1̃ and 𝑃2̃ with P1 and P2 in (4):
(8) 𝜎1 = [𝑃2(1 − 𝑃2) + (1 − 𝜋0)
2 𝑃1(1 − 𝑃1)]
1 2⁄
With 𝜎0̅̅ ̅ and 𝜎1 defined, the asymptotic power for a Z-Test of α level to test our given null 
hypothesis (2), can be determined, where Φ is the standard Normal distribution function: 
(9) 1 − 𝛽 = Φ{
1
𝜎1
[𝑍1−𝛼𝜎0̅̅ ̅ + 𝑛
1 2⁄ 𝑃1(𝜋1 − 𝜋0)]}
Based on this formula for asymptotic power of the test, the total sample size, N, can then be 
determined as follows: 
(10) 𝑁 = 2[(𝑍1−𝛼𝜎0̅̅ ̅ + 𝑍1−𝛽𝜎1)
2
 / (𝑃1(𝜋1 − 𝜋0))
2
]
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2.4 EXACT CONDITIONAL TEST UNDER POISSON ASSUMPTION 
If the disease of interest is rare and has a low incidence rate, a large scale trial may be required. In 
this particular situation, an exact conditional test, where the number of cases in the study can be 
approximated by a Poisson distribution, has been previously proposed (Breslow & Day, 1987; 
Gail, 1AD). Slightly modified by Chan and Bohidar to account for a null hypothesis with a non-
zero lower bound, this Exact Conditional Test procedure, is presented below (Bohidar & Chan, 
1996; Chan & Bohidar, 1998). 
Let X and Y represent the number of cases in the control and test vaccine groups, where 
they independently follow Binomial distributions, BIN(n, P1) and BIN(n, P2), respectively. In the 
case of a rare disease, where n is adequately large and P1 and P2 are adequately small, we can 
assume that nP1 → λ1 and nP2 → λ2.  Therefore, X and Y can be approximated as POI(λ1) and 
POI(λ2), respectively. The total accumulated number of cases observed during the course of the 
trial, X+Y,  is denoted as T. Consequently, the appropriate distribution of Y (number of cases in 
the test vaccine group), conditional upon T = t, for any t ∈ {0, 1 ,2, 3…, T}, can be derived as 
follows: 
𝑋~𝑃𝑂𝐼(𝜆1) 𝑎𝑛𝑑 𝑌~𝑃𝑂𝐼(𝜆2), 𝑤ℎ𝑒𝑟𝑒 𝑋 𝑎𝑛𝑑 𝑌 𝑎𝑟𝑒 𝑖𝑛𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 
𝑇ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒, 𝑇 = 𝑋 + 𝑌~𝑃𝑂𝐼(𝜆1 + 𝜆2) 
𝑃(𝑌 = 𝑘|𝑇 = 𝑡) =
𝑃(𝑌 = 𝑘, 𝑇 = 𝑡)
𝑃(𝑇 = 𝑡)
𝑃(𝑌 = 𝑘, 𝑋 + 𝑌 = 𝑡)
𝑃(𝑇 = 𝑡)
 =
𝑃(𝑌 = 𝑘, 𝑋 = 𝑡 − 𝑘)
𝑃(𝑇 = 𝑡)
=
𝜆2
𝑘
𝑘! ∗
𝜆1
𝑡−𝑘
(𝑡 − 𝑘)!
(𝜆1 + 𝜆2)𝑡
𝑛!
= (
𝑡
𝑘
)
𝜆2
𝑘 𝜆1
𝑡−𝑘
(𝜆1 + 𝜆2)𝑛
= (
𝑡
𝑘
) (
𝜆2
𝜆1 + 𝜆2
)
𝑘
(
𝜆1
𝜆1 + 𝜆2
)
𝑡−𝑘
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𝐿𝑒𝑡 𝛳 =
𝜆2
𝜆1 + 𝜆2
=
𝑛𝑃2
𝑛𝑃1 + 𝑛𝑃2
=
1 − 𝜋
2 − 𝜋
Substituting ϴ into the final step of the derivation above, the conditional distribution of Y given T 
is then shown to follow a Binomial distribution: 
 (11) 𝑌 | 𝑇 ~ 𝐵𝐼𝑁(𝑇, 𝛳) = (𝑇
𝑘
)𝛳𝑘(1 − 𝛳)𝑇−𝑘 
To accommodate for the decreasing nature of ϴ, our hypothesis (2) can then be represented 
accordingly: 
(12)  𝐻0:  𝛳 ≥ 𝛳0   𝑣𝑒𝑟𝑠𝑢𝑠    𝐻1:  𝛳 < 𝛳0 
where 𝛳0 = (1 − 𝜋0)/(2 − 𝜋0). If Yobs is the number of cases observed in the test vaccine group, 
the exact conditional p-value can then be calculated as: 
(13)  𝑝 = Pr[𝑌 ≤ 𝑌𝑜𝑏𝑠| 𝑌~BIN(𝑇, 𝛳0)] =  ∑ (
𝑇
𝑘
)𝛳0
𝑘(1 − 𝛳0)
𝑇−𝑘𝑌𝑜𝑏𝑠
𝑘=0
Similarly, given our hypothesis (2) against a specified alternative, the exact power and critical 
value (Yc) at a pre-specified level (α) can be calculated as such: 
(14) 1 − 𝛽 = Pr[𝑌 ≤ 𝑌𝑐| 𝑌~BIN(𝑇, 𝛳1)] = ∑ (
𝑇
𝑘
)𝛳1
𝑘(1 − 𝛳1)
𝑇−𝑘𝑌𝑐
𝑘=0
𝑤ℎ𝑒𝑟𝑒   𝛳1 = (1 − 𝜋1)/(2 − 𝜋1) 
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With a minimum value of T determined for the level of the test that will also achieve the 
desired minimum power, a vaccine efficacy trial can then be designed around accruing a specified 
total number of cases. The corresponding total sample size (N) for the vaccine efficacy trial can be 
calculated by the following formula: 
(15)  𝑁 ≈ 2 ∗
𝑇
(2−𝜋1)𝑃1
2.5 COMPUTATION AND SOFTWARE 
All formulas and methodology, as described here, were coded with SAS® software (Version 9.4, 
Cary, NC). Aside from assuming equal sample sizes between the control and test groups, all 
formulas were coded exactly as presented by Chan and Bohidar, and are provided in the Appendix 
(Chan & Bohidar, 1998). Using what we refer to as a “brute force” type algorithm, we were able 
to determine the correct minimum number of cases to be accrued over the trial (T), as  required for 
the Exact Conditional approach, and then the projected sample size. The logic of this procedure is 
described below: 
1) Consider all values of T from 1 to 1000
2) Determine a critical value (Yc) for each respective T, if it exists
a) Using equation (14) and considering all Y values ∈  {0, 1 ,2, 3…, T}, Yc is the minimum
value at which power is > the pre-specified minimum power
b) Any values of T without a determined Yc value are no longer considered
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3) Level of the test, for each combination of T and its respective Yc value is considered
a) Only values of T where exact level, using equation (13), is < the pre-specified alpha
are considered
4) Determine the minimum required value of T from this reduced set of T’s
a) The minimum T at which all following T’s increase by a value of 1 without skipping
i) Due to the discrete nature of the Binomial distribution, we want to ensure that if an
extra case is obtained, power does not drop below the pre-specified minimum
power
5) Determine the expected sample size for the trial using equation (15)
2.6 METHODOLOGY EVALUATION 
In their work, Chan and Bohidar compared the statistical power and size of the Exact Conditional 
and Normal Approximation approaches, as well as compared their performance, in terms of the 
sample size requirements. In order to further assess the performance of these methods, we 
expanded upon the set of vaccine efficacy trial scenarios considered in their paper. A scenario, as 
we denoted it, can be described by three primary variables: the incidence of disease in the control 
group (P1), true vaccine efficacy (π1), and the vaccine efficacy lower bound (π0).  
In real-world scenarios, disease incidence can range drastically, depending on a large 
number of factors. In their paper, Chan and Bohidar suggested that the Exact Test has substantially 
less power than the Z-Test when the incidence rate in the control group is > 0.3. Therefore, we 
focused on the rates less than 0.3, stratifying by high, intermediate, and low incidence scenarios. 
The three values of disease incidence of the control group used in this paper were based upon what 
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we considered to be realistic values that might be observed today, for a range of diseases. The 
high incidence value was baselined off of the world-wide incidence of malaria in 2000 
(~0.155), an incidence much higher than observed today, as this was expected to adequately 
represent a realistic upper bound for incidence (World Bank, 2018). For the low incidence 
scenario, an incidence of 0.01 was used, as this was low enough to demonstrate differences 
between the two methods, while still producing realistically viable sample size estimates. 
Similarly, vaccine efficacy values range widely, from 0% up to nearly 100% in real-
world trials. After reviewing a number of different vaccine efficacy trials, we decided to fix the 
true efficacy at an intermediate value of 65%. In addition to a zero lower-bound for the null 
efficacy, a  lower-bound of 15% was also considered, as this represented what we found to be a 
realistic lower-bound in a vaccine efficacy trial design (Alonso et al., 1994; Aronson et al., 2004; 
Cassio de Moraes et al., 1992; Coursaget et al., 1986; Fine et al., 1994; Gross, et al., 1995; Kulkarni 
et al., 2017; Rerks-Ngarm et al., 2009).  
With the scenarios defined as such, the changes in sample size requirements were 
investigated, while simultaneously increasing the minimum pre-specified power, from 80% to 
95%, in increments of 5%, as well as two values for the significance level of the test, 2.5% and 
5.0%. The minimum sample size required under these scenarios was evaluated by the Exact 
Conditional and Normal Approximation approaches, as described in Sections 2.3 and 2.4. 
Furthermore, the validity of the Exact Conditional approach to sample size estimation was 
investigated via simulations. Empirical power was calculated under the same set of scenarios 
described above, allowing us to evaluate the performance of the Exact Conditional approach, in 
terms of power. Briefly, the simulations were performed as follows. The number of cases in the 
control and treatment groups was simulated independently, based on BIN(n, P1) for the control 
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subjects and BIN(n, P2) for the test subjects, where n is 1/2 of the sample size for the scenario, as 
estimated via the Exact Conditional approach. For each simulated trial, a p-value was calculated 
using formula (13). Simulating 2,000,000 trials per scenario, statistical power was then calculated 
as the proportion of those trials in which the null hypothesis was rejected at the pre-specified level 
for that particular scenario. 
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3.0 RESULTS 
Estimates of the sample sizes under a range of  hypothetical vaccine efficacy trial scenarios are 
presented in Tables 1, 2, and 3. Within these tables, we presented identical sets of scenarios, 
except for different disease incidence in the control group (P1), stratified by high, intermediate, 
and low disease incidence.  
Regardless of the specific incidence in the control group, there were a number of 
overarching patterns that arose across the three scenarios. First, the exact power, number of total 
required cases, and exact level remained the same across Tables 1, 2, and 3. As explained in 
Section 2.5, these components were reliant upon the null and true vaccine efficacy values, which 
were identical across the three primary incidence scenarios, thus explaining this particular 
pattern. 
When specifying a smaller alpha level under the same scenario, estimated sample size 
increased. Similarly, when specifying a greater minimum power for two otherwise identical 
scenarios, estimated sample size again increased. This observation was logical, as both decreasing 
alpha and increasing power serve to provide one with greater certainty in the findings of a trial, 
consequently, requiring a greater number of subjects to be accrued. To confirm the trend in the 
relationship between power and sample size, additional scenarios were considered (Figure 1). 
In terms of the vaccine efficacy values, an increase in the efficacy lower bound resulted in 
an increase in sample size for both methods, across all three disease incidence scenarios. To further 
investigate this relationship, as well as the effect of varying the true vaccine efficacy value (π1), 
an additional set of scenarios was considered, where either the efficacy lower bound or true vaccine 
efficacy were changing, while keeping all other parameters fixed (Figure 2). In Figure 2a, with the 
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true efficacy fixed, increasing the efficacy lower bound translated to a decreased effect size and 
therefore, increased sample size. On the contrary, in Figure 2b, with the efficacy lower bound 
fixed, increasing the true efficacy translated to an increased effect size and therefore, decreased 
sample size. These two observations succinctly demonstrated the generally expected relationship 
between effect size and sample size, where sample size estimates increase as effect size decreases. 
The results of the simulations are also presented in Tables 1-3. Within this identified set of 
scenarios, the empirical power was almost always less than the exact power for the targeted number 
of cases. This can be attributed to the fact that, when using the two Binomial distributions to 
simulate our data, many of the “trials” resulted in fewer than the targeted number of cases (T). In 
each of those trials, the exact power could be substantially lower than the targeted power. Although 
theoretically it is possible that there are scenarios in which the empirical (unconditional) power is 
higher than the targeted power, we can generally expect that in regular scenarios when the targeted 
range of statistical power is 70-90%, unconditional power would be lower than exact. 
Furthermore, there are some particular patterns that arose as a result of changes in the 
disease incidence of the control group.  For the case of high incidence, sample size estimates were 
smaller overall. More specifically, comparing a fixed scenario across any two tables, the sample 
size estimates of the Exact Conditional approach increased proportional to the factor decrease in 
the control incidence. Referencing the Exact Conditional sample size formula (15), the sample 
size only relies upon the control incidence via P1 in the denominator, as neither the minimum 
required number of cases (T) nor the true efficacy (π1) rely upon control incidence. On the other 
hand, while a similarly inverse relationship was observed between the Normal Approximation 
sample size and control incidence, this relationship was not exactly proportional as observed with 
20 
the Exact Conditional approach. Likewise, in referencing equations (6) through (10), the 
relationship between sample size and P1 cannot be as easily disentangled. 
The differences in sample size estimates of the Exact Conditional approach and the Normal 
Approximation method were similarly reflected by the efficiency measure in Tables 1-3. Within 
our designated set of scenarios, efficiency values were always less than 100%, indicating that the 
estimated sample sizes via the Normal Approximation were predominantly less than those from 
the Exact Conditional approach. On average, efficiency was overall lowest when incidence was 
highest. In comparing Table 1 and Table 2, there were some individual scenarios where this does 
not hold true, but this is likely attributed to the discrete nature of the Binomial distribution used 
for the Exact Conditional approach.  The higher efficiency observed in Table 3 suggests that, 
under a scenario of low incidence, sample size estimates using the Exact Conditional approach 
should be relatively close to those when using the Normal Approximation approach.
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Table 1. Sample size estimates and power calculations for scenarios of high incidence (P1=0.15, π1 = 0.65). 
Efficacy 
Lower 
Bound 
Pre-specified 
Alpha 
Pre-specified 
Power 
Exact Level 
Exact 
Power 
Simulated 
Power 
Exact Conditional Test Z-Test Efficiency  
(Z-Test/Exact) 
(%) (π0) (%) (%) (%) (%) (%) 
Total # of 
Cases 
Expected 
Sample 
Size 
Asymptotic 
Sample 
Size 
(T) (N) (N) 
0 2.5 80.0 2.35 86.2 82.4 37 366 300 82.0 
0 2.5 85.0 2.18 89.6 87.8 42 416 342 82.2 
0 2.5 90.0 2.00 92.1 91.6 47 466 400 85.8 
0 2.5 95.0 2.20 96.2 95.8 56 554 492 88.8 
0.15 2.5 80.0 2.45 85.2 82.1 51 504 422 83.7 
0.15 2.5 85.0 1.94 86.9 86.4 57 564 482 85.5 
0.15 2.5 90.0 2.02 92.1 91.8 67 662 562 84.9 
0.15 2.5 95.0 2.02 96.3 96.4 82 810 690 85.2 
0 5.0 80.0 4.36 83.4 80.3 28 278 236 84.9 
0 5.0 85.0 4.01 87.7 86.5 33 326 274 84.1 
0 5.0 90.0 4.03 92.8 92.3 40 396 326 82.3 
0 5.0 95.0 4.27 96.7 96.3 49 484 410 84.7 
0.15 5.0 80.0 4.05 85.6 84.4 44 436 332 76.2 
0.15 5.0 85.0 4.11 89.0 88.1 49 484 384 79.3 
0.15 5.0 90.0 4.13 91.6 91.1 54 534 456 85.4 
0.15 5.0 95.0 4.49 96.0 95.6 66 652 572 87.7 
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Table 2. Sample size estimates and power calculations for scenarios of intermediate incidence (P1=0.05, π1 = 0.65). 
Efficacy 
Lower 
Bound 
Pre-specified 
Alpha 
Pre-specified 
Power 
Exact Level 
Exact 
Power 
Simulated 
Power 
Exact Conditional Test Z-Test Efficiency  
(Z-Test/Exact) 
(%) (π0) (%) (%) (%) (%) (%) 
Total # of 
Cases 
Expected 
Sample 
Size 
Asymptotic 
Sample 
Size 
(T) (N) (N) 
0 2.5 80.0 2.35 86.2 81.4 37 1098 968 81.4 
0 2.5 85.0 2.18 89.6 86.8 42 1246 1106 86.8 
0 2.5 90.0 2.00 92.1 90.7 47 1394 1294 90.7 
0 2.5 95.0 2.20 96.2 95.1 56 1660 1600 95.1 
0.15 2.5 80.0 2.45 85.2 81.1 51 1512 1364 81.1 
0.15 2.5 85.0 1.94 86.9 85.5 57 1690 1556 85.5 
0.15 2.5 90.0 2.02 92.1 91.0 67 1986 1814 91.0 
0.15 2.5 95.0 2.02 96.3 95.8 82 2430 2232 95.8 
0 5.0 80.0 4.36 83.4 79.0 28 830 762 79.0 
0 5.0 85.0 4.01 87.7 85.5 33 978 886 85.5 
0 5.0 90.0 4.03 92.8 91.4 40 1186 1054 91.4 
0 5.0 95.0 4.27 96.7 95.7 49 1452 1332 95.7 
0.15 5.0 80.0 4.05 85.6 83.3 44 1304 1072 83.3 
0.15 5.0 85.0 4.11 89.0 87.2 49 1452 1242 87.2 
0.15 5.0 90.0 4.13 91.6 90.2 54 1600 1474 90.2 
0.15 5.0 95.0 4.49 96.0 95.0 66 1956 1854 95.0 
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Table 3. Sample size estimates and power calculations for scenarios of low incidence (P1=0.01, π1 = 0.65). 
Efficacy 
Lower 
Bound 
Pre-specified 
Alpha 
Pre-specified 
Power 
Exact Level 
Exact 
Power 
Simulated 
Power 
Exact Conditional Test Z-Test Efficiency  
(Z-Test/Exact) 
(%) (π0) (%) (%) (%) (%) (%) 
Total # of 
Cases 
Expected 
Sample 
Size 
Asymptotic 
Sample 
Size 
(T) (N) (N) 
0 2.5 80.0 2.35 86.2 80.9 37 5482 4980 90.8 
0 2.5 85.0 2.18 89.6 86.4 42 6224 5696 91.5 
0 2.5 90.0 2.00 92.1 90.3 47 6964 6666 95.7 
0 2.5 95.0 2.20 96.2 94.8 56 8298 8244 99.4 
0.15 2.5 80.0 2.45 85.2 80.7 51 7556 7014 92.8 
0.15 2.5 85.0 1.94 86.9 85.1 57 8446 7998 94.7 
0.15 2.5 90.0 2.02 92.1 90.6 67 9926 9330 94.0 
0.15 2.5 95.0 2.02 96.3 95.6 82 12150 11488 94.6 
0 5.0 80.0 4.36 83.4 78.6 28 4150 3924 94.6 
0 5.0 85.0 4.01 87.7 85.1 33 4890 4562 93.3 
0 5.0 90.0 4.03 92.8 91.1 40 5926 5434 91.7 
0 5.0 95.0 4.27 96.7 95.5 49 7260 6864 94.6 
0.15 5.0 80.0 4.05 85.6 82.9 44 6520 5512 84.5 
0.15 5.0 85.0 4.11 89.0 86.9 49 7260 6388 88.0 
0.15 5.0 90.0 4.13 91.6 89.9 54 8000 7582 94.8 
0.15 5.0 95.0 4.49 96.0 94.8 66 9778 9540 97.6 
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Figure 1. Sample size estimates versus pre-specified power (%). 
Scenario parameters fixed as follows: P1=0.01, π0=0.15 π1=0.65, Alpha=5% 
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Figure 2. Sample size estimates under varying levels of vaccine efficacy lower bound (a) 
and true vaccine efficacy (b). 
Scenario parameters fixed as follows: (a): P1=0.01, π0=0.00, Alpha=5%, Power=80% 
 (b): P1=0.01, π1=0.65, Alpha=5%, Power=80% 
π0 π1 
(a) (b) 
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4.0 DISCUSSION 
In planning and designing a vaccine efficacy trial, both the Exact Conditional approach and 
Normal Approximation approach are viable methods to sample size estimation, each with their 
own advantages and disadvantages. The Normal Approximation procedure represents a 
reasonable and less specialized approach, requiring minimal programming and computational 
complexity. This technique is also conveniently available in some statistical packages, such as 
PASS (NCSS LLC, Kaysville, Utah). Therefore, the simplicity of implementing it is one of its 
strong advantages. The Exact Conditional method, on the other hand, requires more initial 
programming to be performed, but is still relatively fast to execute on a modern-day computer. 
In terms of sample size requirements, we found that the Exact Conditional method 
provided estimates consistently larger than those of the Normal Approximation, particularly, 
up to 25% larger in scenarios of higher incidence. These differences, however, became 
substantially smaller under low incidence scenarios, with most being under 10%, but no 
greater than ~16%. Our observations agreed with those by Chan and Bohidar. They concluded 
that, under scenarios of low incidence and fixed large sample sizes (~4,000+), the Exact 
Conditional Test performed similarly to the Z-Test, in terms of power, and for some cases, 
tended to be even more powerful (Chan & Bohidar, 1998).  
Despite the involved complexity of the Exact Conditional approach, there are some 
considerations to be made that may lend it some favorability. From a practicality and a trial design 
standpoint, this approach may be more favorable, due to its conditionality upon a required number 
of cases. With such an approach, a trial would be designed to accrue a fixed number of events, and 
a situation where the pre-specified statistical power is not achieved would therefore be avoided. 
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While a given trial is in motion, these total number of cases can be easily monitored, 
effectively serving as an indicator of the progress of the trial. Depending on the timeline and 
trial schedule, decisions to end the trial early or extend it, in order to accrue more cases, can 
be supported with a quick reference to this easily accessible value. On the contrary, under the 
fixed sample size/duration trial design, there is the possibility that the trial may be 
underpowered, due to a lower incidence rate in the control group than anticipated. An important 
and sometimes overlooked aspect of a biostatistician’s job lies in his or her ability to clearly 
communicate the rationale of their design and analysis plan to non-statistician investigators on the 
trial. Correspondingly, the required total number of cases condition and its utility as an indicator 
of trial’s progress may be a more intuitive and easily understood measure. 
While either of the methods we have investigated are generally reasonable for determining 
a sample size that should adequately power a trial, careful considerations should be given to the 
congruency between the methods used for planning, design, and final analysis of the collected 
data. As illustrated by the results of our simulations, inconsistencies between these major stages 
of a clinical trial could lead to underpowered trials. After evaluating the required sample size using 
the conditional approach, we simulated our trial data unconditionally via two independent 
Binomial distributions, with probabilities equal to the incidence rates in the control and test groups. 
Our approach to the simulation was more representative of the real-world, where trials are designed 
to accrue and observe a fixed number of subjects, and then run for a fixed amount of time. Such 
inconsistence between our method of sample size estimation and the design of the simulations led 
to a notable number of “trials” under each scenario accruing less than the required number of cases. 
This then resulted in nearly all of the scenarios we presented having a simulated power that was 
less than the exact power. This suggests that in a real-world situation, given the Exact Conditional 
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sample size estimate, a fixed sample size/duration trial may likely be underpowered, due to the 
minimum number of cases condition not being satisfied.  
In practice, it is also possible that sample size may be estimated using the Normal 
Approximation, yet, in the analysis stage, the Exact Conditional Test may be used. This might 
present a problem, similar to what was observed in our simulations, with differences in exact 
versus empirical power. Considering that the Normal Approximation sample size estimates, within 
the scenarios we defined, were consistently less than those of the Exact Conditional approach, 
these trials would be significantly less likely to accrue the necessary number of cases. Thus, if 
analyzed with the Exact Conditional Test, there is a high probability that the trial will be 
underpowered. It is therefore crucial that the method used for sample size estimation matches that 
which is used for the data analysis. 
As discussed earlier, prolonging a trial is a possible solution to accruing more cases when 
the required number of cases condition is not met, but this may not always be a logistically or 
financially viable option. In an effort to avoid under-powering a trial, we propose a potential 
inflation of the sample size estimate be used during the trial design stage of a fixed number of 
events trial to ensure that, with a given probability, the required number of cases will be observed 
(Flahault, Cadilhac, & Thomas, 2005). The specific probability used, however, should be further 
explored by investigators, in order to best determine a sample size that is manageable and 
reasonable, given the budget and other constraints of the trial. In combination with careful 
considerations of congruency in the trial design and analysis methodology, this will help to ensure 
that a trial achieves its desired power, allowing investigators to confidently draw conclusions. 
 In designing a clinical trial, one of the essential considerations to be made is the sample 
size estimation, which targets the pre-specified statistical power, minimizing the chance of a false-
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negative conclusion. Incorrectly estimated sample sizes could lead to unnecessary costs or 
inconclusive study results. In this paper, we assessed the practicality of the Exact Conditional Test 
under Poisson Assumption and Z-Test Normal Approximation approaches to sample size 
estimation and power calculation for vaccine efficacy trials (Chan & Bohidar, 1998). In trials 
where incidence in the control group is high, the Normal Approximation is a reasonable and easy 
to implement approach that should adequately power the trial. For trials with low incidence (< 
0.01), the Exact Conditional approach may be more favorable, as it may provide greater power to 
the trial, at the cost of a marginal increase in sample size. To increase the likelihood that the 
required number of cases is accrued in a trial, we advise the use of a strategic sample size inflation, 
thereby decreasing the chances of an underpowered trial. Lastly, to better ensure the trial’s targeted 
power is achieved, it is important that the methodology used for sample size estimation, study 
design, and data analysis are congruent. 
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APPENDIX:  SAS CODE 
***************************************************************************** 
MACRO: Vaccine Efficacy Trial Sample Size using the Exact Conditional Test  
***************************************************************************** 
 
-Calculates the exact power and sample size for a vaccine efficacy trial, 
using an Exact Conditional Test under Poisson Assumption 
-All formulas are based upon (Chan & Bohidar, 1998) 
-Assumes equal sample size between test and control groups 
-Vaccine efficacy here is defined as (1-relative risk) of participants in the 
test group having the disease, relative to the control group 
-This method defines the minimum # of cases required to achieve the pre-
specified power, where the trial is then designed around accruing >= this # 
of total cases 
 
*Required inputs are as follows (only values between 0 and 1 are accepted): 
 
 P1     = incidence in the control group 
 VE1    = true efficacy of test vaccine, under the alternative 
 VE0    = minimum efficacy of test vaccine, under the null (NOTE: must 
be less than VE1) 
 Power  = pre-specified power desired to achieve 
 Alpha  = pre-specified maximum one-sided level of the test 
 Output = name of temporary dataset to where the results will be output 
 
When this MACRO is run, a temporary dataset will be output, along with a 
printout of this dataset;  
 
%MACRO SampleSize_ExactConditional(P1=, VE1=, VE0=, Power=, Alpha=, Output= 
); 
%LET c = 1;  
OPTIONS SPOOL; 
/*Calculates and assigns theta values as macro variables for the power 
calculation based on input VE0 VE1 */ 
DATA _NULL_; 
 teta0=(1-&VE0)/(1+&c-&VE0); 
 teta1=(1-&VE1)/(1+&c-&VE1); 
 CALL SYMPUT("theta0", teta0); 
 CALL SYMPUT("theta1", teta1); 
RUN; 
 
/*Loops through all possible T's (where T is total # of cases accumulated) 1-
1000, calculates the power and level at ALL y(obs) values*/ 
DATA temp; 
 RETAIN VE1 P1 T Yc power level  n2; 
 VE1=&VE1; 
 P1=&P1; 
 VE0=&VE0; 
 alpha=&alpha;  *Alpha is the nominal significance level; 
 powerreq=&power; *powerreq is the required power as specified; 
  DO T=1 TO 1000; 
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   Yc=0; 
   level=0; 
   power=0; 
   DO x=1 TO T; 
     Yc=x;  
     power = PROBBNML(&theta1,T,x); *power is 
the exact power of the test; 
     level = PROBBNML(&theta0,T,x); *level is 
the exact level of the test; 
     n2=T/((&c+1-&VE1)*(&P1)); 
     N=ceil(n2)*2; 
     OUTPUT; 
   END; 
   OUTPUT; 
  END; 
DROP x; 
RUN; 
 
/*Removes any observations were level is > pre-specified ALPHA */ 
DATA temp; 
 SET temp; 
 IF (level <= &alpha AND power >= &power); 
RUN;  
 
/*Keeps 1st observation PER T where minimum power is reached (this is the 
critical value Yc) */ 
DATA temp; 
 SET temp; 
 BY t; 
 IF first.t=1; 
RUN; 
 
/* Creates FLAG1 variable where flag1=1 if current T is previous T+1 */ 
DATA temp; 
 SET temp; 
 IF T = (LAG1(T)+1) THEN flag1=1; 
 ELSE flag1=0; 
RUN;  
 
/* Creates 20 lag variables (F1-F20) based on the flag1 variable */ 
DATA temp; 
 SET temp; 
 F1 = LAG1(FLAG1); F2 = LAG2(FLAG1); F3 = LAG3(FLAG1); F4 = LAG4(FLAG1); 
F5 = LAG5(FLAG1); 
 F6 = LAG6(FLAG1); F7 = LAG7(FLAG1); F8 = LAG8(FLAG1); F9 = LAG9(FLAG1); 
F10 = LAG10(FLAG1); 
 F11 = LAG11(FLAG1); F12 = LAG12(FLAG1); F13 = LAG13(FLAG1); F14 = 
LAG14(FLAG1); F15 = LAG15(FLAG1); 
 F16 = LAG16(FLAG1); F17 = LAG17(FLAG1); F18 = LAG18(FLAG1); F19 = 
LAG19(FLAG1); F20 = LAG20(FLAG1); 
RUN; 
 
 
/* Creates new FLAG2 variable where FLAG2=1 if all F1-F20=1, else FLAG2=0 */ 
/* logic: if we count back 20 from the last FLAG2=0, then we will end up at 
the first T when power stabilizes and T's become consecutive, increasing 
1 at a time without skipping*/ 
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DATA temp; 
 SET temp; 
 IF F1=1 AND F2=1 AND F3=1 AND F4=1 AND F5=1 AND F6=1 AND F7=1  
 AND F8=1 AND F9=1 AND F10=1 AND F11=1 AND F12=1 AND F13=1 AND  
 F14=1 AND F15=1 AND F16=1 AND F17=1 AND F18=1 AND F19=1 AND F20=1 THEN 
FLAG2=1; 
 ELSE FLAG2=0; 
RUN; 
 
/* Keeps only FLAG2=0 */ 
DATA temp; 
 SET temp; 
 WHERE FLAG2=0; 
 DROP F1-F20 FLAG1; 
RUN; 
 
/*Assigns the maximum value of T in the previous datastep to MACRO variable 
"maxT", then subtracts 20 */ 
DATA _NULL_; 
 SET temp; 
 CALL SYMPUT("maxT", MAX(T)-20); 
RUN; 
 
/*Identifies the lowest minimum T for which power will always be >= pre-
specified power based, on maxT in previous step */ 
DATA &output LABEL; 
 SET temp; 
 IF T=&maxT; 
 DROP FLAG2; 
 FORMAT power level alpha powerreq PERCENT10.2; 
 LABEL  P1 = "Incidence Rate in Control" 
   VE1 = "True Efficacy of Test Vaccine" 
   VE0 = "Efficacy Lower Bount" 
   alpha = "Pre-Specified Level" 
   powerreq = "Required Power" 
   level = "Exact Level" 
   power = "Exact Power" 
   T = "Total # of cases (Exact Conditional)" 
   N = "Expected Sample Size (Exact Conditional)"; 
RUN; 
 
PROC DELETE DATA=temp; 
RUN; 
 
/* Prints output dataset */ 
PROC PRINT DATA=&output LABEL; 
 VAR P1 VE1 VE0 powerreq alpha power level N; 
RUN; 
 
%MEND; 
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***************************************************************************** 
MACRO: Vaccine Efficacy Trial Sample Size using the Z Test Normal 
Approximation 
***************************************************************************** 
 
-Calculates an estimated asymptotic sample size for a vaccine efficacy trial 
using a normal approximation approach 
-All formulas are based upon (Chan & Bohidar, 1998) 
 
*Required inputs are as follows (only values between 0 and 1 are accepted): 
 
 P1     = incidence in the control group 
 VE1    = true efficacy of test vaccine, under the alternative 
 VE0    = minimum efficacy of test vaccine, under the null (NOTE: must 
be less than VE1) 
 Power  = pre-specified power desired to achieve 
 Alpha  = pre-specified maximum one-sided level of the test 
 Output = name of temporary dataset to where the results will be output 
 
When this MACRO is run, a temporary dataset will be output, along with a 
printout of this dataset;  
 
%MACRO SampleSize_NormalApprox(P1=, VE1=, VE0=, Power=, Alpha=, Output= ); 
%LET c = 1;  
OPTIONS SPOOL; 
 
/*Calculates and assigns p2 (incidence in test group) */ 
DATA _NULL_; 
 p2=(1-&VE1)*&P1; 
 CALL SYMPUT("p2", p2); 
RUN; 
 
/* Calculates all the necessary parameters (sigma0 and sigma1) for the Z-test 
via Normal Approximation and assigns them to macro variables */ 
DATA _NULL_; 
 sigma1=(&P2*(1-&P2)+(1/&c)*((1-&VE0)**2)*(&P1)*(1-&P1))**(1/2); 
 a=(1-&VE0)*(1+&c*&P1)+&c+&p2; 
 b=(1-&VE0)*(&c*&P1+&p2); 
 P2z=((a-((a**2)-4*b*(1+&c))**(1/2))/(2*(1+&c))); 
 p1z=p2z/(1-&VE0); 
 sigma0=(p2z*(1-p2z)+(1/&c)*((1-&VE0)**2)*(p1z)*(1-p1z))**(1/2); 
 CALL SYMPUT("sigma0", sigma0); 
 CALL SYMPUT("sigma1", sigma1); 
RUN; 
 
/* Calculates the Normal Approximation Sample Size */ 
DATA &output LABEL; 
 P1=&p1; 
 VE1=&VE1; 
 VE0=&VE0; 
 powerreq=&power; 
 alpha=&alpha; 
 zalpha=QUANTILE("norm", &alpha); 
 zbeta=QUANTILE("norm", 1-&power); 
 N2z=((zalpha*&sigma0+zbeta*&sigma1)**2)/((&P1*(&VE1-&VE0))**2); *sample 
size for vaccine group; 
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 Nz=ceil(n2z)*2; *total sample size (when c=1, this is simply 
doubling; 
 DROP zalpha zbeta N2z; 
 FORMAT power level alpha powerreq PERCENT10.2; 
 LABEL  P1 = "Incidence Rate in Control" 
   VE1 = "True Efficacy of Test Vaccine" 
   VE0 = "Efficacy Lower Bount" 
   alpha = "Pre-Specificed Level" 
   powerreq = "Required Power" 
   Nz = "Expected Sample Size (Normal Approximation)"; 
RUN;  
 
/* Prints output dataset */ 
PROC PRINT DATA=&output LABEL; 
 VAR P1 VE1 VE0 powerreq alpha Nz; 
RUN; 
 
%MEND; 
 
 
/* Example execution of macros */ 
%SampleSize_ExactConditional(P1=0.05, VE1=0.65, VE0=0.15, Power=0.85, 
Alpha=0.05, Output=sampleExact); 
%SampleSize_NormalApprox(P1=0.05, VE1=0.65, VE0=0.15, Power=0.85, Alpha=0.05, 
Output=sampleNormal); 
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